<p><strong>Chronic Hepatitis B</strong>: Telbivudine is indicated for the treatment of chronic hepatitis B in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. The following points should be considered when initiating therapy with Telbivudine:<br />
&nbsp;</p>

<ul>
	<li>This indication is based on virologic, serologic,&nbsp;biochemical&nbsp;and histologic responses in nucleoside treatment na&iuml;ve adult patients with HBeAg positive and HBeAg negative chronic hepatitis B with compensated liver disease&nbsp;</li>
	<li>For HBeAg-positive patients, Telbivudine should only be initiated in patients with HBV DNA less than 9 log10&nbsp;copies per mL and ALT greater than or equal to 2x Upper Limit of Normal (ULN) prior to treatment.</li>
	<li>For HBeAg-negative patients, Telbivudine should only be initiated in patients with HBV DNA less than 7 log10&nbsp;copies per mL prior to treatment.</li>
	<li>On-treatment response should guide continued therapy&nbsp;</li>
	<li>Telbivudine has not been evaluated in patients co-infected with&nbsp;HIV, HCV or&nbsp;HDV.</li>
	<li>Telbivudine has not been evaluated in&nbsp;liver transplant&nbsp;recipients or in patients with decompensated liver disease.</li>
	<li>Telbivudine has not been studied in well-controlled trials for the treatment of patients with established nucleoside analog reverse transcriptase inhibitor-resistant hepatitis B virus infection, but is expected to be cross-resistant to lamivudine.</li>
	<li>The safety and efficacy of Telbivudine have not been evaluated in Black/African American or Hispanic patients</li>
</ul>